Chemical changes in fibronectin may restart cell senescence through altered integrin binding
After senescent cells are removed, chemically altered fibronectin may trigger renewed senescence and damaging exchange with vascular tissue. The hypothesis would lose support if selective correction of its altered binding sites, with confirmed target engagement, leaves recurrence unchanged.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 5 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Structural protein
Fibronectin
A matrix protein whose attachment sites interact with integrins
Where this hypothesis actsChemically modified matrix sites containing isoDGR after senescent cell removal
Hypotheses on this target 1
Lower level
Higher level
Replacement
Protection from degradation
Function preservation
Remodelling
Crosslink prevention
What is proposed
Selectively mask isoDGR sites to block their interaction with integrins
With whatNot stated in the record
HowSelective masking of accessible isoDGR sites while preserving matrix mechanics and ordinary attachment-site density
Possible result
Possible reduction in recurrent cellular senescence, damaging exchange with vascular tissue and SPV_1
From the recordИзбирательное устранение активности isoDGR при сохранении механики матрикса должно уменьшить SPV_1.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Removing damaged cells may leave behind something that makes their replacements become damaged too. The unexpected move is to locate that remaining cause in the chemical structure of the material surrounding cells, rather than only in surviving cells or tissue stiffness. This is a proposal generated by the pipeline, not a measured result showing that the proposed source restarts damage.
- Spontaneous chemical change converts attachment sites in fibronectin into isoDGR sites.
- The converted sites change how fibronectin binds to integrins on cell surfaces.
- Removal of senescent cells leaves the proposed chemical source in the surrounding scaffold.
- The remaining altered sites are proposed to make newly encountering cells attach and become active in harmful ways.
- Those interactions are proposed to restart cellular senescence.
- Renewed senescence is proposed to restore damaging exchanges with tissue associated with blood vessels.
Replacing people working from a damaged instruction sheet leaves the same faulty instructions for the next group. The proposed chemical change is like damage to the sheet that survives every change of staff.
Where the picture breaks: The surrounding material does not contain literal instructions that cells must obey. The proposal depends on particular molecular contacts causing renewed senescence, and the supplied evidence does not establish that consequence.
- Master questionstep 01 of 04
Aging processes may reinforce one another, so interrupting a shared cause could benefit several body systems at once.
Rests on: The goal seeks a shared cause whose disruption could weaken several interacting forms of age-related damage.
AssumptionThe goal assumes that a shared cause exists and can be targeted precisely enough to produce benefits across systems; the supplied material does not establish that premise.
- Goal pillarstep 02 of 04
Weakening the mutual reinforcement of age-related damage is the chosen route toward benefits across body systems.
Rests on: The master question explicitly identifies interacting aging processes as a reason to seek a shared causal target.
Stated in the chain - Gap questionstep 03 of 04
Damage passing between tissues might resume after confirmed removal of persistently senescent cells, which have stopped dividing. Independently changing the mechanics of the extracellular matrix, the material surrounding and supporting cells, is proposed as a way to investigate whether it retains a source of renewed senescence.
Rests on: The preceding goal motivates looking for a source that sustains damage between tissues, but does not identify cell removal or matrix mechanics as the route to finding it.
LeapThe supplied chain and sources do not establish that damage resumes after confirmed cell removal or that matrix mechanics preserve its cause. Those missing connections motivate this question but are not supplied as findings.
- Hypothesisstep 04 of 04
Chemically changed fibronectin, a protein in the surrounding tissue scaffold, is proposed to retain the source of recurrence. Deamidation, a chemical change to an amino acid building block, converts NGR, an asparagine–glycine–arginine sequence, into isoDGR, an isoaspartate–glycine–arginine sequence with an altered backbone connection. The changed sites are proposed to alter binding to integrins, cell-surface proteins that connect cells to their surroundings, and thereby restart senescence after the original cells are removed.S1S2
Rests on: The preceding question supplies the idea of a persistent source in the surrounding material. Source S1, an abstract from The Journal of Biological Chemistry in 2006, reports conversion of a fibronectin site into an integrin-binding site; it does not establish recurrence after cell removal or an effect with matrix mechanics preserved. Source S2, published in Atherosclerosis in 2021, reports increased integrin binding by altered fibronectin on immune cells and cells lining blood vessels; it does not establish renewed senescence after cell removal or selective prevention of recurrence. These findings support the chemical and binding links that the proposal borrows, not its complete causal sequence.
Supported by literature
What is carried, and what is not. The two screened sources cited here support the first two links: chemical conversion of fibronectin sites and altered binding to cell-surface attachment proteins, without establishing recurrence after cell removal. No supplied source establishes the full sequence from a surviving chemical change to renewed senescence and damaging exchanges between tissues.
Where the reasoning is carried by something unstated · 2
- Master question. The goal assumes that a shared cause exists and can be targeted precisely enough to produce benefits across systems; the supplied material does not establish that premise.
- Gap question. The supplied chain and sources do not establish that damage resumes after confirmed cell removal or that matrix mechanics preserve its cause. Those missing connections motivate this question but are not supplied as findings. Establish the missing link before relying on this step.
How a result here could mislead · 3
- A reduction in recurrence after blocking isoDGR could be credited to its chemical identity even if the intervention also changes tissue mechanics or ordinary cell attachment. What closes it: The proposed matching of initial stiffness, stress relaxation—the fading of force while material remains deformed—and ordinary attachment-site density must be verified after intervention as well. Blocking and adding back isoDGR-containing fragments must demonstrably change access to those sites without introducing the competing changes; reducing total fibronectin alone does not meet this requirement.
- Senescent cells found after removal could be surviving members of the original population rather than cells newly driven into senescence by the altered scaffold. What closes it: Removal must be confirmed, and the test must distinguish surviving original cells from newly senescent cells. Otherwise, persistence and recurrence remain conflated.
- Reduced cell attachment or activation could be read as prevention of senescence and damage between tissues, although those are different outcomes. What closes it: The test must measure renewed senescence and damage between tissues separately from attachment and activation. The supplied outcome label SPV_1 has no definition, measurement method or timing, so those must be specified before a change in that quantity can support the claimed outcome.
What would make this wrong. The central causal claim would fail if selective blocking of accessible isoDGR, with its action verified and mechanics and ordinary attachment sites preserved, left newly arising senescence unchanged after confirmed removal of the original senescent cells. That result would weaken this hypothesis without by itself deciding among loss of mechanical protection, delayed immune removal and continuing damage generated inside cells.
What it would change. If the proposal held, removing senescent cells would leave a chemically stored cause capable of rebuilding the damaging process. Work seeking a shared intervention against aging would then have to account for the surrounding material as well as the cells, with selective correction of altered attachment sites becoming a candidate intervention. Even a successful test would not establish benefits across multiple body systems or longer life; the supplied specification also leaves the relevant species, population and timescale unresolved.
Sources read · 7
Spontaneous formation of L-isoaspartate and gain of function in fibronectin. · The Journal of biological chemistry · 2006
“we show that deamidation of Asn263 at the Asn-Gly-Arg (NGR) site in fibronectin N-terminal region generates an alpha(v)beta3-integrin binding site containing the L-isoDGR sequence”
Does not settle: The abstract does not establish recurrence of cell senescence after senescent-cell removal, persistence of these sites in vascular tissue, SPV_1 effects, selective isoDGR inactivation while preserving matrix mechanics, or the relevant population and timescale.
Aging-induced isoDGR-modified fibronectin activates monocytic and endothelial cells to promote atherosclerosis. · Atherosclerosis · 2021
“Age-damaged fibronectin features isoDGR motifs that increase binding to integrins on the surface of monocytes, macrophages, and endothelial cells.”
Does not settle: The source text does not establish recurrence of cellular senescence after senescent-cell removal, persistence of a pathological state in vascular tissue, or whether selective isoDGR neutralization preserves matrix mechanics and reduces SPV_1.
Monocyte adhesion to atherosclerotic matrix proteins is enhanced by Asn-Gly-Arg deamidation. · Scientific reports · 2017
“We report for the first time that asparagine deamidation of the extracellular matrix proteins FN and TNC in particular can enhance monocyte adhesion via isoDGR interactions with integrin α v β 3 .”
Does not settle: This source does not establish that altered fibronectin restarts cellular senescence after senescent-cell removal, persists as a recurrence source, activates new cells, or that selectively eliminating isoDGR activity reduces SPV_1. Its reported functional evidence concerns monocyte-macrophage adhesion in vitro and atherosclerotic plaque context.
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. · The Journal of biological chemistry · 2008
“Asparagine deamidation at the NGR sequence in the 5th type I repeat of fibronectin (FN-I5) generates iso DGR, an v 3 inte-grin-binding motif regulating endothelial cell adhesion and pro-liferation.”
Does not settle: This source does not establish that isoDGR sites restart cellular senescence after senescent-cell removal, persist as a source of recurrence in vascular tissue, drive damaging vascular metabolism, or that selectively eliminating isoDGR activity reduces SPV_1 while preserving matrix mechanics.
Recombinant humanized type III collagen improves ovarian function via ITGA2-mediated mitochondrial function restoration in granulosa cells and extracellular matrix remodeling. · Regenerative biomaterials · 2026
“These results implied that rhCol III may bind to ITGA2 on GCs and activate the PI3K/Akt signaling pathway.”
Does not settle: Источник не исследует фибронектин, превращение NGR в isoDGR, дезамидирование, сохранение ковалентного состояния матрикса после удаления сенесцентных клеток или возобновление старения и повреждающего обмена с сосудистой тканью.
Aging Biology of Bone-to-Tendon Healing and the Epigenetic Clock: A Biological-Age Readout of Rotator Cuff Healing Capacity. · Biomedicines · 2026
“Second is cellular senescence and the senescence-associated secretory phenotype (SASP). As senescent cells accumulate, the SASP suppresses matrix synthesis and angiogenesis”
Does not settle: Источник не устанавливает роль фибронектина, превращения NGR в isoDGR, изменения связывания с интегринами, сохранения патологического состояния после удаления сенесцентных клеток или эффекта избирательного устранения активности isoDGR.
“This mechanism plays a critical role in cellular senescence and organ fibrosis ( ).”
Does not settle: The source does not establish fibronectin deamidation, NGR-to-isoDGR conversion, altered integrin binding, senescent-cell clearance, recurrence of senescence, vascular effects, or selective isoDGR targeting.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Does changing tissue scaffolding explain whether damage returns across tissues after confirmed removal of persistently aging cells?
Original wording · exactly as the pipeline generated it
Возобновляется ли межтканевое повреждение после подтверждённого удаления хронически стареющих клеток, и покажет ли независимое изменение механики матрикса, что именно он сохраняет источник повторного клеточного старения?
What this question is asking
The question concerns whether removing persistently damaged cells ends a continuing source of tissue injury or only temporarily reduces its effects. These cells are described as senescent: they remain in an altered state and can release substances that affect surrounding tissue. The question asks whether, after the original stress ends and their removal is confirmed, these cells and damage return in skin and blood vessels, and whether tissue function remains impaired over weeks or months. It also asks whether independently changing the physical properties of the extracellular matrix, the scaffolding around cells, changes that recurrence compared with leaving those properties unchanged. This assumes that the scaffolding can retain a physical memory of earlier damage and cause replacement cells to become senescent, an assumption the supplied sources do not establish.
- Cellular senescence
- A persistent altered cell state commonly involving withdrawal from cell division and changes in what the cell releases. Senescence includes varied states; it is not simply another name for a cell being old, and the question concerns states that persist and contribute to damage.
- Senescence markers
- Measured features used to identify or estimate senescence. A reduction in these features is not equivalent to direct proof that all relevant senescent cells have been removed.
- Verified clearance
- Confirmed removal of the relevant senescent-cell population. This is a requirement of the question, distinct from observing fewer markers or better tissue function.
- Secretion
- The release of substances by cells into their surroundings. The proposed mechanism depends on harmful effects of substances released by senescent cells, but the supplied findings do not establish the complete chain leading to recurrent damage.
- Extracellular matrix or tissue scaffolding
- Material outside cells that surrounds and supports them. Its maintenance and physical properties are distinct features, so evidence about matrix maintenance alone does not establish a mechanical cause.
- Matrix mechanics
- The physical behavior of tissue scaffolding, including how strongly it resists deformation. The question asks whether changing these properties independently affects renewed senescence.
- Mechanical memory
- Here, the proposed persistence of a physical tissue condition after the original stress or damaging cells have gone. The supplied sources do not establish that this condition causes replacement cells to become senescent.
- Damage across tissues
- Injury involving more than one tissue, here particularly skin and blood vessels. Damage in both tissues would not by itself prove that one caused damage in the other.
- Navitoclax
- The drug used in S2, where treatment reduced senescence markers and improved blood-vessel function. Those reported effects do not establish lasting recovery after verified clearance.
- Doxorubicin
- The chemotherapy drug used to induce the vascular change studied in S3. This exposure is a specific injury setting and does not establish what happens in persistent senescence more generally.
- Arteries and the aorta
- Arteries carry blood away from the heart; the aorta is the main artery leaving it. Their ability to widen, contract, and resist stretching describes different aspects of blood-vessel function.
- Dermis
- The supporting layer of skin beneath its outer surface. S5 reports a reduction in senescent cells in its upper portion in tissue maintained outside the body.
Removing senescent cells reduces the source of damaging secretion, while mechanical memory in the extracellular matrix can recreate damaging senescent states after removal.
The extracellular matrix is the material surrounding and supporting cells, and its mechanical properties describe how it resists forces or changes shape. The assumption is that this material retains a harmful physical condition after damaged cells are removed and then drives other cells into the same damaging state. If established, this would explain why removing the current cells might leave the cause of their replacement intact.
The supplied search results did not return work establishing the complete claim. S2 reports improved blood-vessel function alongside reduced senescence markers, and S3 reports prevention of increased aortic stiffness with senescent-cell removal. S9 summarizes earlier work linking cell clearance with reduced secretion associated with senescence and improved matrix maintenance. These findings concern benefits of reducing senescence; they do not establish that retained matrix mechanics recreate senescent cells after verified clearance. S7 proposes possible disruption of matrix maintenance, but does not demonstrate the reverse causal step from altered matrix mechanics to renewed senescence. This bounded evidence does not show that the premise is false.S2S3S7S9
The same question asked without the part nothing read establishes:
- After the original stress ends and persistent senescent cells are demonstrably removed, does damage recur across skin and blood vessels, and does independently changing matrix mechanics alter that recurrence?
- Does verified removal of persistent senescent cells produce sustained reductions in senescence and sustained functional recovery in skin and blood vessels?
- Damage returns and depends on scaffold mechanics If independently changing scaffold mechanics changes renewed senescence and damage after verified clearance, that would support a causal contribution from the remaining scaffold. Cell removal would then reduce the current damaging population while leaving a physical condition capable of helping replenish it.
- Damage returns without established scaffold causation Recurrence would show that verified removal did not secure lasting recovery under the conditions observed. If changing scaffold mechanics does not alter recurrence, or its contribution remains unresolved, recurrence alone would not identify the scaffold as the remaining cause.
- Damage does not return Sustained recovery after verified removal would be consistent with eliminating a continuing source of damage over the observed period. A scaffold-driven return of senescence would then be unnecessary to explain the measured outcome, although the result would remain limited to the tissues and duration observed.
The proposed chain begins with senescent cells releasing substances that contribute to tissue damage. Removing those cells could reduce that source, but if altered scaffolding causes other cells to become senescent, the source could be replenished and damage could return. If removal instead produces lasting recovery, continued damage would not require such replenishment under the conditions observed. Mistaking an initial improvement for lasting recovery would overstate what cell removal accomplishes; attributing recurrence to scaffolding without evidence would assign the cause prematurely. The supplied evidence supports some benefits associated with reducing senescence, but does not establish this proposed recurrence chain.
Удаление клеток RL-2 уменьшает источник секреции; механическая память RL-1 допускает повторное образование повреждающих состояний после удаления.
После прекращения нагрузки избыток стареющих состояний в коже и сосудах сокращается за недели и месяцы, функции выходят из ухудшенного плато.
Не установлено, устраняет ли удаление клеток причину устойчивого повреждения или временно сокращает популяцию, которую заново создаёт матрикс.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Источник рецидива сохраняется в химически изменённых участках фибронектина. Самопроизвольное дезамидирование превращает последовательности NGR в изоаспартат-содержащие последовательности isoDGR и меняет взаимодействие белка с интегринами. После удаления сенесцентных клеток эти участки продолжают задавать патологическое прикрепление и активацию новых клеток, возобновляя старение и повреждающий обмен с сосудистой тканью. Состояние хранится в ковалентной структуре белка. Избирательное устранение активности isoDGR при сохранении механики матрикса должно уменьшить SPV_1.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
На матриксах с одинаковыми начальной жёсткостью, релаксацией и плотностью обычных участков прикрепления частота повторного старения зависит от количества доступных isoDGR. Их избирательное маскирование предотвращает рецидив, а добавление определённых isoDGR-содержащих фрагментов возвращает его. Изменение одной только релаксации при фиксированной доступности isoDGR даёт существенно меньший эффект. Если химическая коррекция с подтверждённым действием на мишень не изменяет рецидив, гипотеза уступает механическому или внутриклеточному объяснению.
Would tell it apart from at least one rival. The prediction specifies observable prevention and restoration of recurrence, a comparative effect of relaxation, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Химически определённые пептиды и реконструированные матриксы позволяют разделить состав лигандов и механику. Нужны методы, различающие аспартат и изоаспартат, а также контроль доступности участков связывания. Простое уменьшение общей массы фибронектина будет недостаточно избирательной проверкой.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
На матриксах с одинаковыми начальной жёсткостью, релаксацией и плотностью обычных участков прикрепления частота повторного старения зависит от количества доступных isoDGR. Их избирательное маскирование предотвращает рецидив, а добавление определённых isoDGR-содержащих фрагментов возвращает его. Изменение одной только релаксации при фиксированной доступности isoDGR даёт существенно меньший эффект. Если химическая коррекция с подтверждённым действием на мишень не изменяет рецидив, гипотеза уступает механическому или внутриклеточному объяснению.
- What would separate them
Removing senescent cells may renew damage by removing their mechanical protection predicts: После одинакового подтверждённого удаления исходных клеток инертные микрогели, воспроизводящие их расположение и способность рассеивать энергию, предотвращают ранние пики деформации ядер, последующее появление новых сенесцентных клеток и повреждение связанной сосудистой ткани. Контрольные микрогели того же размера и начальной жёсткости, но с другой диссипацией, такого эффекта не дают. Первые повреждения возникают в клетках, которые ещё не вступили в синтез ДНК. Если механическая замена при подтверждённом восстановлении распределения нагрузки не предотвращает рецидив, гипотеза уступает химическому, генотоксическому или регуляторному объяснению.
- Rival 02 of 03What would separate them
Delayed immune clearance may drive recurring waves of senescent cells and tissue damage predicts: При одинаковых составе матрикса, начальной клеточной нагрузке и интегральной цитотоксической активности сокращение задержки иммунного ответа переводит повторные волны сенесценции в затухающее восстановление. Подача той же суммарной активности с исходным запаздыванием сохраняет рецидив. Измеренный сдвиг фазы между появлением новых сенесцентных клеток и их удалением заранее предсказывает время следующего пика. Сохранение рецидива после подтверждённой коррекции задержки опровергает это объяснение как достаточное.
- Rival 03 of 03What would separate them
Mobile genetic element cutting may restart cellular senescence after senescent-cell removal predicts: После подтверждённого удаления исходной сенесцентной популяции в отслеживаемых ранее несенесцентных клетках сначала возрастает активность LINE-1 и число повреждений ДНК, затем появляются устойчивое прекращение деления и секреторный фенотип. Подавление LINE-1 с последующим восстановлением эндонуклеазно-активным ORF2 возвращает рецидив; восстановление вариантом с отключённой эндонуклеазой при сопоставимой экспрессии этого не делает. Механическая коррекция матрикса и маскирование isoDGR не устраняют этот контраст. Отсутствие зависимости от эндонуклеазы при подтверждённом действии вмешательства опровергает гипотезу.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.